New trial finds arthritis drug no better than standard care for severe covid-19

(BMJ) Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published byThe BMJ today.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news